Pancreatic cancer breakthrough drug Rasonque doubles survival time in trial

Dr. Monique Yohanan discusses a pancreatic cancer breakthrough involving the drug Rasonque. Clinical trial results from Revolution Medicines show Rasonque doubles survival time for stage 4 patients compared to chemotherapy.

Pancreatic cancer treatment receives a major boost as Dr. Monique Yohanan analyzes clinical trial results for Rasonque, a breakthrough drug from Revolution Medicines. The trial shows stage 4 patients achieved 13.2 months of median survival compared to just 6.7 months with standard chemotherapy. This development offers new hope against a disease with a historic three percent stage 4 survival rate.